In this enlightening discussion, Allison DeAngelis, a prominent biotech commentator, and Matt Glein, CEO of Roivant, delve into the current surge in funding for neuropsychiatric diseases, spotlighting Seaport Therapeutics’ impressive $225 million Series B round. They weigh the merits of diversified versus focused pipelines and examine the hub-and-spoke model's implications. The conversation touches on the promising Phase 2 results from Alto Neurosciences and Vertex's innovative pain management approach, ultimately painting a vibrant picture of the biotech landscape.
